Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong

PRECIGEN, INC.

PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.
Cash, cash equivalents, and investments $100.4M as of Dec 31, 2025, expected to fund to cash flow break-even.
Patient hub enrollment >300; payer coverage ~215M lives (~90% insured US); CMS assigned permanent J-code effective Apr 1, 2026.
Net loss attributable to common shareholders $429.6M ($1.37/sh) vs $126.2M ($0.47) in 2024, driven by non-cash warrant and preferred stock items.
R&D expenses down 22.1% YoY; SG&A up 69.8% reflecting commercial launch investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.